​

Biomea Fusion (BMEA) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

BMEA Stock Forecast

Biomea Fusion (BMEA) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $20.20, with a high of $40.00 and a low of $10.00. This represents a 3266.67% increase from the last price of $0.60.

- $8 $16 $24 $32 $40 High: $40 Avg: $20.2 Low: $10 Last Closed Price: $0.6

BMEA Stock Rating

Biomea Fusion stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (78.57%), 3 Hold (21.43%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 3 11 Strong Sell Sell Hold Buy Strong Buy

BMEA Price Target Upside V Benchmarks

TypeNameUpside
StockBiomea Fusion3266.67%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.60$0.60$0.60
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2624--17
Sep, 2624--17
Aug, 2624--17
Jul, 2624--17
Jun, 2624--17
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 24, 2025Oppenheimer$10.00$2.79258.42%1566.67%
Oct 31, 2024Joseph CatanzaroPiper Sandler$19.00$10.3483.75%3066.67%
Oct 30, 2024Peter LawsonBarclays$11.00$12.06-8.79%1733.33%
Oct 22, 2024Joseph PantginisH.C. Wainwright$40.00$11.24255.87%6566.67%
Sep 27, 2024Joseph CatanzaroPiper Sandler$10.00$9.901.01%1566.67%
Jun 07, 2024Joseph PantginisH.C. Wainwright$15.00$4.24253.77%2400.00%
Jun 07, 2024George FarmerScotiabank$21.00$11.2786.34%3400.00%
Jun 07, 2024Peter LawsonBarclays$5.00$11.27-55.63%733.33%
Jun 14, 2022Joseph PantginisH.C. Wainwright$16.00$8.5088.24%2566.67%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 07, 2026Brookline CapitalBuyinitialise
Sep 30, 2026CitigroupMarket OutperformMarket Outperformhold
Aug 24, 2026H.C. WainwrightBuyBuyhold
Aug 11, 2026CitigroupBuyBuyhold
May 05, 2026CitigroupBuyOutperforminitialise
Mar 27, 2026CitigroupBuyBuyhold
Jan 13, 2026Rodman & RenshawBuyBuyinitialise
Aug 28, 2025JefferiesBuyinitialise
Aug 05, 2025OppenheimerOutperformOutperformhold
Oct 31, 2024Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.44$-3.83$-1.18---
Avg Forecast$-3.32$-3.89$-3.55$-3.30$-3.38$-2.13
High Forecast$-3.14$-3.44$-2.82$-0.84$-0.88$-2.13
Low Forecast$-3.50$-4.18$-4.30$-5.24$-4.97$-2.13
Surprise %3.61%-1.54%-66.76%---

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast-$10.00M$1.88M$4.33M$29.19M$198.99M
High Forecast-$10.00M$1.88M$4.33M$29.19M$198.99M
Low Forecast-$10.00M$1.88M$4.33M$29.19M$198.99M
Surprise %------

Net Income Forecast

$-200M $-160M $-120M $-80M $-40M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-117.25M$-138.43M$-61.80M---
Avg Forecast$-107.69M$-130.06M$-121.44M$-161.05M$-163.59M$-72.79M
High Forecast$-107.02M$-117.41M$-96.21M$-28.75M$-30.15M$-72.79M
Low Forecast$-119.37M$-142.71M$-146.68M$-178.61M$-169.36M$-72.79M
Surprise %8.89%6.43%-49.11%---

BMEA Forecast FAQ

Is Biomea Fusion stock a buy?

Biomea Fusion stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Biomea Fusion is a favorable investment for most analysts.

What is Biomea Fusion's price target?

Biomea Fusion's price target, set by 14 Wall Street analysts, averages $20.2 over the next 12 months. The price target range spans from $10 at the low end to $40 at the high end, suggesting a potential 3266.67% change from the previous closing price of $0.6.

How does Biomea Fusion stock forecast compare to its benchmarks?

Biomea Fusion's stock forecast shows a 3266.67% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Biomea Fusion over the past three months?

  • October 2026: 28.57% Strong Buy, 57.14% Buy, 0% Hold, 0% Sell, 14.29% Strong Sell.
  • September 2026: 28.57% Strong Buy, 57.14% Buy, 0% Hold, 0% Sell, 14.29% Strong Sell.
  • August 2026: 28.57% Strong Buy, 57.14% Buy, 0% Hold, 0% Sell, 14.29% Strong Sell.

What is Biomea Fusion’s EPS forecast?

Biomea Fusion's average annual EPS forecast for its fiscal year ending in December 2026 is $-3.3, marking a 179.66% increase from the reported $-1.18 in 2025. Estimates for the following years are $-3.38 in 2027, and $-2.13 in 2028.

What is Biomea Fusion’s revenue forecast?

Biomea Fusion's average annual revenue forecast for its fiscal year ending in December 2026 is $4.33M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $29.19M, and $198.99M for 2028.

What is Biomea Fusion’s net income forecast?

Biomea Fusion's net income forecast for the fiscal year ending in December 2026 stands at $-161M, representing an 160.61% increase from the reported $-61.797M in 2025. Projections indicate $-164M in 2027, and $-72.794M in 2028.